- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Insights 656 results
Client Alert
February 2, 2023
It’s Not Just for Dietary Supplements Anymore: FTC Revises and Expands Guidance for Health Claims
Client Alert
January 31, 2023
U.S. House of Representatives Establishes Select Committee on Strategic Competition with China
Client Alert
January 13, 2023
Pharma Investment Trend Report: What We’re Watching in 2023
Client Alert
January 11, 2023
House Republicans Establish New Select Subcommittees Focused on Pandemic and “Weaponization of the Federal Government”
Client Alert
January 10, 2023
MDD Certificates Remain Valid: European Commission Proposes Longer Transition Periods for MDR Compliance
Client Alert
January 9, 2023
Nearly a Century in the Making: Congress Modernizes FDA’s Regulation of Cosmetics
Client Alert
January 9, 2023
Not Quite the Titanic: The Food and Drug Omnibus Reform Act Rescues Some FDA Policy Initiatives
Client Alert
January 6, 2023
Preventing Organizational Conflicts of Interest in Federal Acquisition Act
Newsletter
January 3, 2023
Health Headlines – January 3, 2023
Client Alert
December 19, 2022
FDA Warns Drug & Device Firms Against Delaying & Limiting Facility Inspections in New Draft Guidance
Thought Leadership
December 15, 2022
Podcast - Healthcare, Episode 4: Teladoc Health: Balancing Risks With Rewards in the Rapidly Growing Telehealth Industry
Client Alert
December 8, 2022
Goodbye Reboxing! European Court of Justice Restricts Parallel Imports of Medicines